Every 10-Q that Hims & Hers Health, Inc. (HIMS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow HIMS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HIMS filings page.
Hims & Hers Health, Inc. reported strong top-line growth but a sharp swing to losses for the quarter and six months ended June 30, 2026. Revenue rose to $753.2M in the quarter from $544.8M a year earlier, and to $1.36B for the first half from $1.13B, driven by expansion in the United States and rapid growth in international markets, including recent acquisitions.
Despite higher gross profit, the company recorded a net loss of $86.3M for the quarter and $178.4M year-to-date, compared with net income of $42.5M and $92.0M in the prior-year periods. The shift reflects substantially higher operating expenses, including marketing, general and administrative costs, amortization of newly acquired intangibles, and $38.1M in restructuring and related charges tied to changes in the U.S. weight-loss offering. The company also booked fair-value adjustments on contingent consideration and equity securities and accrued $62.5M for legal contingencies.
Total assets increased to $3.63B from $2.15B, mainly from the $968.5M Eucalyptus acquisition and the $153.0M YourBio acquisition, which together added significant goodwill and intangible assets. Liabilities rose to $3.30B, including $1.37B of convertible senior notes and large deferred and earn-out obligations, while stockholders’ equity declined to $324.1M. Operating cash flow remained positive at $53.4M for the first half, supported by working-capital movements and non-cash expenses, and cash and cash equivalents ended at $609.8M plus $231.2M of short-term investments.
Hims & Hers Health reported Q1 2026 revenue of $608.1 million, up from $586.0 million a year earlier, but shifted from profit to a net loss of $92.1 million, or $(0.40) per diluted share, versus diluted EPS of $0.20 in Q1 2025.
Results were pressured by $33.5 million in non-recurring restructuring and related charges tied to a U.S. weight-loss offering shift and $17.6 million of fair value losses on liabilities plus $9.7 million on equity securities. The company still generated $89.4 million in operating cash flow and ended the quarter with $222.3 million in cash and $528.6 million in short-term investments.
Hims & Hers closed the $153.0 million YourBio acquisition, continued integrating prior Medici and Zava deals, and outlined a planned Eucalyptus purchase for up to $1.15 billion. It also carried $1.0 billion of 0% convertible notes due 2030 and recorded a $15.0 million accrual related to an FTC ROSCA investigation.
Hims & Hers Health reported strong growth for Q3 2025. Revenue reached $598.976 million, up from $401.556 million a year ago, with gross profit of $442.058 million. For the nine months, revenue was $1.729 billion versus $995.375 million, and net income totaled $107.764 million compared with $100.013 million.
Quarterly net income was $15.774 million, reflecting higher operating expenses and a $7.626 million change in fair value of liabilities, partly offset by $8.042 million of other income and a $3.551 million tax benefit. Deferred revenue rose to $118.458 million from $75.285 million as more customers adopted prepaid offerings.
The balance sheet expanded following strategic moves. The company issued 2030 convertible notes, with convertible senior notes, net, at $971.023 million, and ended with $345.778 million in cash and cash equivalents and $722.306 million in investments. Total assets increased to $2.233 billion, including $259.236 million of goodwill and $194.931 million of intangible assets. Hims & Hers acquired Zava Global GmbH for EUR 219.2 million to expand in the U.K. and EU and invested in manufacturing and fulfillment capacity.